论文部分内容阅读
目的探讨通脉口服液对柯萨奇病毒感染的小鼠心肌炎模型的治疗作用和抑制病毒效果。方法用通脉口服液和病毒唑注射液分别于模型小鼠(CVB3m所致Balb/c小鼠心肌炎)连续给药7d,第8日取心肌和血标本;观察病死率、心肌炎发病率和心肌病理以及心肌组织与血的病毒滴度。结果通脉口服液能明显降低心肌炎模型小鼠心肌中的病毒滴度,其中高剂量组的作用强度明显大于低剂量组和病毒唑对照组;通脉口服液可以明显降低模型小鼠心肌炎的病死率(高剂量与低剂量),明显减少心肌组织病理积分(高剂量)。结论通脉口服液对心肌炎具有较明显的治疗作用,可以明显减轻病毒对心肌细胞直接损害。
Objective To investigate the therapeutic effect of Tongmai Oral Liquid on Coxsackie virus-infected mouse myocarditis model and its antiviral effect. Methods Tongmai Oral Liquid and Ribavirin injection were used in model mice (CVB3m-induced Balb/c mouse myocarditis) for 7 days. Myocardium and blood samples were collected on the 8th day; Mortality, myocarditis incidence, and myocardium were observed. Pathology and viral titer of myocardial tissue and blood. Results Tongmai Oral Liquid can significantly reduce the viral titer in myocardium of myocarditis model mice. The effect of high dose group was significantly higher than that of low dose group and ribavirin control group; Tongmai Oral Liquid can significantly reduce the death of myocarditis in model mice. Rates (high and low doses) significantly reduced myocardial histopathologic scores (high doses). Conclusion Tongmai Oral Liquid has a significant therapeutic effect on myocarditis and can significantly reduce the direct damage of the myocardium to the virus.